ArticleBMC geriatrics2024
Association between sarcopenia and new-onset chronic kidney disease among middle-aged and elder adults: findings from the China Health and Retirement Longitudinal Study.
Article in BMC geriatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Uric acid to high-density lipoprotein cholesterol ratio as a novel biomarker for sarcopenia: a national study with machine learning insights.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease.The journal of nutrition, health & aging · 2026Article
- Impact of occult renal dysfunction on postoperative acute kidney injury and late prognosis in elderly patients undergoing coronary artery bypass.BMC nephrology · 2026Observational
- The triglyceride HDL cholesterol ratio predicts sarcopenia risk in an aging National cohort from China.Scientific reports · 2026Article
- Sarcopenia risk along the cardiovascular-kidney-metabolic syndrome spectrum: synergistic effects of multisystem burden and physical inactivity.BMC public health · 2025Article
- Revisiting successful aging through a machine learning approach to quantifying the influence of chronic diseases.Scientific reports · 2025Article
- Association of Difference Between eGFR From Cystatin C and Creatinine and Serum GDF-15 With Adverse Outcomes in Diabetes Mellitus.Journal of cachexia, sarcopenia and muscle · 2025Article
- Association between high-sensitivity C-reactive protein, cystatin C and all-cause mortality in middle-aged and elderly participants with sarcopenia.Aging clinical and experimental research · 2025Article
- Functional Performance Decline Outperforms Sarcopenia and Its Components in Predicting New-Onset Chronic Kidney Disease: A Nationwide Multicenter Study.Kidney medicine · 2025Article
- Inhibiting Myostatin Expression by the Antisense Oligonucleotides Improves Muscle Wasting in a Chronic Kidney Disease Mouse Model.International journal of molecular sciences · 2025Article
- Association between chronic kidney disease and sarcopenia and emerging treatment strategies.Frontiers in nutrition · 2025Review
- Association between cumulative average triglyceride glucose-body mass index and the risk of CKD onset.Frontiers in endocrinology · 2025Article
- Biochemical indicators, physical activity, and functional performance in elderly CKD patients: A cross-sectional study.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia is a senile syndrome of age-related muscle loss. It is thought to affect the development of chronic kidney disease and has a serious impact on the quality of life of the elder adults. Little is known about the association between sarcopenia and new-onset chronic kidney disease in middle-aged and elder adults. Using nationally representative data from the China Health and Retirement Longitudinal Study (CHARLS), we conducted a longitudinal analysis to investigate the association between sarcopenia status and new-onset chronic kidney disease in middle-aged and elder adults in China.
methodsThe study population consisted of 3676 participants aged 45 or older selected from 2011 CHARLS database who had no history of chronic kidney disease at the baseline and completed the follow-up in 2015. A multivariate cox regression model was employed to examine the association between sarcopenia and the incidence of new-onset chronic kidney disease.
resultsFollowed up for 4 years, a total of 873 (22.5%) new cases of chronic kidney disease occurred. Among them, participants diagnosed with sarcopenia (HR1.45; 95% CI 1.15-1.83) were more likely to develop new-onset chronic kidney disease than those without sarcopenia. Similarly, patients with sarcopenia were more likely to develop new-onset chronic kidney disease than those with possible sarcopenia (HR 1.27; 95%CI 1.00-1.60). Subgroup analysis revealed that elder adults aged between 60 and 75 years old (HR 1.666; 95%CI 1.20-22.28), with hypertension (HR 1.57; 95%CI 1.02-2.40), people with sarcopenia had a significantly higher risk of developing new-onset chronic kidney disease than those without sarcopenia (all P < 0.05).
conclusionMiddle-aged and elder adults diagnosed with sarcopenia have a higher risk of developing new-onset chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.